ReviewHeliyon2020
Current challenges and possible future developments in personalized psychiatry with an emphasis on psychotic disorders.
Review in Heliyon, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The range of countermeasures to reduce inequalities in mental health care for socially marginalized or medically vulnerable adults: a PRISMA systematic review.BMC health services research · 2026Pooled it
- A generalizable computational framework for integrating heterogeneous biomarkers into interpretable scalar risk representations.BMC medical informatics and decision making · 2026Article
- Innovation at the Intersection: Emerging Translational Research in Neurology and Psychiatry.Cells · 2024Article
- Changing trends in the global burden of mental disorders from 1990 to 2019 and predicted levels in 25 years.Epidemiology and psychiatric sciences · 2023Article
- The Inflammatory Signals Associated with Psychosis: Impact of Comorbid Drug Abuse.Biomedicines · 2023Review
- Genomic regulatory sequences in the pathogenesis of bipolar disorder.Frontiers in psychiatry · 2023Review
- Inflammation and viral infection as disease modifiers in schizophrenia.Frontiers in psychiatry · 2023Review
- Schizophrenia: A Narrative Review of Etiopathogenetic, Diagnostic and Treatment Aspects.Journal of clinical medicine · 2022Article
- Human-Induced Pluripotent Stem Cell Technology: Toward the Future of Personalized Psychiatry.Journal of personalized medicine · 2022Review
- Acoustic and Facial Features From Clinical Interviews for Machine Learning-Based Psychiatric Diagnosis: Algorithm Development.JMIR mental health · 2022Article
- Vulnerability factors and neuropsychiatric disorders: What could be learned from individual variability in cognitive functions.Frontiers in psychology · 2022Article
- Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.Frontiers in psychiatry · 2022Article
- Evaluating Methylation of the Oxytocin Receptor Gene and the Oxytocin Intergenic Region.Methods in molecular biology (Clifton, N.J.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A personalized medicine approach seems to be particularly applicable to psychiatry. Indeed, considering mental illness as deregulation, unique to each patient, of molecular pathways, governing the development and functioning of the brain, seems to be the most justified way to understand and treat disorders of this medical category. In order to extract correct information about the implicated molecular pathways, data can be drawn from sampling phenotypic and genetic biomarkers and then analyzed by a machine learning algorithm. This review describes current difficulties in the field of personalized psychiatry and gives several examples of possibly actionable biomarkers of psychotic and other psychiatric disorders, including several examples of genetic studies relevant to personalized psychiatry. Most of these biomarkers are not yet ready to be introduced in clinical practice. In a next step, a perspective on the path personalized psychiatry may take in the future is given, paying particular attention to machine learning algorithms that can be used with the goal of handling multidimensional datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.